This pathway ties in with both the innate and acquired immune systems as well-established modifiers of atherosclerosis initiation and progression [15], as well as the human findings that anti-IL-1b treatment decreased cardiovascular events in the CANTOS trial [16]. Here, IL1B is linked to atherosclerosis.